The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.

MBX Biosciences, Inc.’s MBX share price has dipped by 14.00%, which has investors questioning if this is right time to buy.

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs ... patients who discussed and received weight loss surgery between 2000 and 2020.

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications ... When diet and exercise aren't enough to lose weight, bariatric surgery can become an option. Yet a new national survey by Orlando ...